WATERTOWN, Mass.--(BUSINESS WIRE)--Nov. 25, 2013-- Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present on December 3 at 2:50 p.m. ET during the Deutsche Bank 2013 BioFest, taking place in Boston, MA.
The session will be conducted as a fireside chat, or interview, format and will be webcast live. The live webcast and replay can be accessed by visiting the Investor homepage section of Enanta’s website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for approximately 30 days.
About Enanta
Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. Enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with AbbVie), NS5A (partnered with Novartis) and nucleotide polymerase – as well as a host-targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Additionally, Enanta has created a new class of antibiotics, called Bicyclolides, for the treatment of multi-drug resistant bacteria, with a focus on developing an intravenous and oral treatment for hospital and community MRSA (methicillin-resistant Staphylococcus aureus) infections.
Source: Enanta Pharmaceuticals, Inc.
Investor Contact
Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710
cmiceli@enanta.com